Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 65. More products

PERINDOPRIL ERBUMINE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Captopril (Noyada): general benefit, Limited Use 707, 723, Not a benefit
  • Cilazapril (Inhibace): general benefit, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit

3 more in the class list below

Apo-Perindopril · DIN 02289261 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Perindopril · DIN 02289261 Manufacturer: Apotex Inc.; listing date 2018-04-30 Health Canada: Marketed since 2020-12-18 · brand APO-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Perindopril: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77465 · Verify on the e-Formulary ↗ (DIN 02289261)

Source record
DIN 02289261: Apo-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id APX Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02289261 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77465
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: shortage reported ended 2026-06-18 (report last updated 2026-06-18); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02289261
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Perindopril · DIN 02459817 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Perindopril · DIN 02459817 Manufacturer: Auro Pharma Inc.; listing date 2018-04-30 Health Canada: Marketed since 2018-03-07 · brand AURO-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Perindopril: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94713 · Verify on the e-Formulary ↗ (DIN 02459817)

Source record
DIN 02459817: Auro-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id AUR Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02459817 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94713
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: active shortage (reported 2026-06-09, estimated to end 2026-09-30, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02459817
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Coversyl · DIN 02123274 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Coversyl (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Coversyl · DIN 02123274 Manufacturer: Servier Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 1994-12-31 · brand COVERSYL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Servier canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16880 · Verify on the e-Formulary ↗ (DIN 02123274)

Source record
DIN 02123274: Coversyl Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id SEV Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.7943; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02123274 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16880
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: resolved shortage (ended 2025-02-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02123274
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Perindopril Erbumine · DIN 02527200 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Perindopril Erbumine · DIN 02527200 Manufacturer: Jamp Pharma Corporation; listing date 2023-01-31 Health Canada: Marketed since 2022-12-15 · brand JAMP PERINDOPRIL ERBUMINE · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Perindopril Erbumine: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101623 · Verify on the e-Formulary ↗ (DIN 02527200)

Source record
DIN 02527200: Jamp Perindopril Erbumine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id JPC Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527200 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101623
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527200
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Perindopril Erbumine · DIN 02482924 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Perindopril Erbumine · DIN 02482924 Manufacturer: Mantra Pharma Inc.; listing date 2021-09-30 Health Canada: Marketed since 2019-07-23 · brand M-PERINDOPRIL ERBUMINE · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Perindopril Erbumine: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97332 · Verify on the e-Formulary ↗ (DIN 02482924)

Source record
DIN 02482924: M-Perindopril Erbumine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id MAT Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482924 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97332
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: resolved shortage (ended 2025-09-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482924
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Perindopril · DIN 02474824 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Perindopril · DIN 02474824 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-06-28 Health Canada: Marketed since 2019-04-11 · brand MAR-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Perindopril: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96501 · Verify on the e-Formulary ↗ (DIN 02474824)

Source record
DIN 02474824: Mar-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id MAR Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474824 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96501
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474824
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Perindopril · DIN 02476762 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Perindopril · DIN 02476762 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2019-06-28 Health Canada: Marketed since 2019-03-22 · brand MINT-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Perindopril: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96760 · Verify on the e-Formulary ↗ (DIN 02476762)

Source record
DIN 02476762: Mint-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id MIN Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02476762 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96760
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02476762
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Perindopril · DIN 02489015 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Perindopril · DIN 02489015 Manufacturer: Nora Pharma; listing date 2020-07-31 Health Canada: Marketed since 2019-10-24 · brand NRA-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Perindopril: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97907 · Verify on the e-Formulary ↗ (DIN 02489015)

Source record
DIN 02489015: NRA-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id NRA Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489015 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97907
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489015
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Perindopril · DIN 02470675 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Perindopril · DIN 02470675 Manufacturer: Pharmascience Inc.; listing date 2018-04-30 Health Canada: Marketed since 2018-03-07 · brand PMS-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Perindopril: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95968 · Verify on the e-Formulary ↗ (DIN 02470675)

Source record
DIN 02470675: PMS-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id PMS Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02470675 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95968
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: resolved shortage (ended 2018-10-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02470675
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Perindopril Erbumine · DIN 02479877 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Perindopril Erbumine · DIN 02479877 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-07-31 Health Canada: Marketed since 2019-02-13 · brand PERINDOPRIL ERBUMINE · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Perindopril Erbumine: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97044 · Verify on the e-Formulary ↗ (DIN 02479877)

Source record
DIN 02479877: Perindopril Erbumine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id SIV Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479877 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97044
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479877
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Perindopril Erbumine · DIN 02481634 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Perindopril Erbumine · DIN 02481634 Manufacturer: Sanis Health Inc.; listing date 2020-07-31 Health Canada: Marketed since 2022-08-04 · brand PERINDOPRIL ERBUMINE · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Perindopril Erbumine: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97209 · Verify on the e-Formulary ↗ (DIN 02481634)

Source record
DIN 02481634: Perindopril Erbumine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id SAI Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481634 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97209
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: resolved shortage (ended 2024-03-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481634
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Perindopril Erbumine · DIN 02470225 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Perindopril Erbumine · DIN 02470225 Manufacturer: Sandoz Canada Inc.; listing date 2018-04-30 Health Canada: Marketed since 2018-03-05 · brand SANDOZ PERINDOPRIL ERBUMINE · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Perindopril Erbumine: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95921 · Verify on the e-Formulary ↗ (DIN 02470225)

Source record
DIN 02470225: Sandoz Perindopril Erbumine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id SDZ Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02470225 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95921
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: resolved shortage (ended 2018-10-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02470225
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Perindopril · DIN 02464985 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Perindopril · DIN 02464985 Manufacturer: Teva Canada Limited; listing date 2018-04-30 Health Canada: Marketed since 2018-03-07 · brand TEVA-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Perindopril: Formulary list price $0.1632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95319 · Verify on the e-Formulary ↗ (DIN 02464985)

Source record
DIN 02464985: Teva-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id TEV Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1632; ministry $0.1632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02464985 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95319
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632 Apo-Perindopril · DIN 02289261 · $0.1632 Auro-Perindopril · DIN 02459817 · $0.1632 Coversyl · DIN 02123274 · $0.1632 Jamp Perindopril Erbumine · DIN 02527200 · $0.1632 Jamp-Perindopril · DIN 02477009 · $0.1632 M-Perindopril Erbumine · DIN 02482924 · $0.1632 Mar-Perindopril · DIN 02474824 · $0.1632 Mint-Perindopril · DIN 02476762 · $0.1632 NRA-Perindopril · DIN 02489015 · $0.1632 PMS-Perindopril · DIN 02470675 · $0.1632 Perindopril Erbumine · DIN 02479877 · $0.1632 Perindopril Erbumine · DIN 02481634 · $0.1632 Sandoz Perindopril Erbumine · DIN 02470225 · $0.1632
Shortage status: resolved shortage (ended 2025-11-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02464985
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Perindopril · DIN 02289288 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Perindopril · DIN 02289288 Manufacturer: Apotex Inc.; listing date 2018-04-30 Health Canada: Marketed since 2020-12-18 · brand APO-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Perindopril: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77466 · Verify on the e-Formulary ↗ (DIN 02289288)

Source record
DIN 02289288: Apo-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id APX Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2042; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02289288 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77466
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Auro-Perindopril · DIN 02459825 · $0.2042 Coversyl · DIN 02123282 · $0.2042 Jamp Perindopril Erbumine · DIN 02527219 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 M-Perindopril Erbumine · DIN 02482932 · $0.2042 Mar-Perindopril · DIN 02474832 · $0.2042 Mint-Perindopril · DIN 02476770 · $0.2042 NRA-Perindopril · DIN 02489023 · $0.2042 PMS-Perindopril · DIN 02470683 · $0.2042 Perindopril Erbumine · DIN 02479885 · $0.2042 Perindopril Erbumine · DIN 02481642 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: shortage reported ended 2026-06-18 (report last updated 2026-06-18); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02289288
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Perindopril · DIN 02459825 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Perindopril · DIN 02459825 Manufacturer: Auro Pharma Inc.; listing date 2018-04-30 Health Canada: Marketed since 2018-03-07 · brand AURO-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Perindopril: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94714 · Verify on the e-Formulary ↗ (DIN 02459825)

Source record
DIN 02459825: Auro-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id AUR Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2042; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02459825 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94714
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Apo-Perindopril · DIN 02289288 · $0.2042 Coversyl · DIN 02123282 · $0.2042 Jamp Perindopril Erbumine · DIN 02527219 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 M-Perindopril Erbumine · DIN 02482932 · $0.2042 Mar-Perindopril · DIN 02474832 · $0.2042 Mint-Perindopril · DIN 02476770 · $0.2042 NRA-Perindopril · DIN 02489023 · $0.2042 PMS-Perindopril · DIN 02470683 · $0.2042 Perindopril Erbumine · DIN 02479885 · $0.2042 Perindopril Erbumine · DIN 02481642 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: active shortage (reported 2026-06-09, estimated to end 2026-09-30, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02459825
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Coversyl · DIN 02123282 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Coversyl (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Coversyl · DIN 02123282 Manufacturer: Servier Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 1994-12-31 · brand COVERSYL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Servier canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16879 · Verify on the e-Formulary ↗ (DIN 02123282)

Source record
DIN 02123282: Coversyl Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id SEV Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.9943; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02123282 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16879
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Apo-Perindopril · DIN 02289288 · $0.2042 Auro-Perindopril · DIN 02459825 · $0.2042 Jamp Perindopril Erbumine · DIN 02527219 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 M-Perindopril Erbumine · DIN 02482932 · $0.2042 Mar-Perindopril · DIN 02474832 · $0.2042 Mint-Perindopril · DIN 02476770 · $0.2042 NRA-Perindopril · DIN 02489023 · $0.2042 PMS-Perindopril · DIN 02470683 · $0.2042 Perindopril Erbumine · DIN 02479885 · $0.2042 Perindopril Erbumine · DIN 02481642 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: resolved shortage (ended 2026-04-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02123282
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Perindopril Erbumine · DIN 02527219 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Perindopril Erbumine · DIN 02527219 Manufacturer: Jamp Pharma Corporation; listing date 2023-01-31 Health Canada: Marketed since 2022-12-15 · brand JAMP PERINDOPRIL ERBUMINE · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Perindopril Erbumine: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101626 · Verify on the e-Formulary ↗ (DIN 02527219)

Source record
DIN 02527219: Jamp Perindopril Erbumine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id JPC Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2042; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527219 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101626
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Apo-Perindopril · DIN 02289288 · $0.2042 Auro-Perindopril · DIN 02459825 · $0.2042 Coversyl · DIN 02123282 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 M-Perindopril Erbumine · DIN 02482932 · $0.2042 Mar-Perindopril · DIN 02474832 · $0.2042 Mint-Perindopril · DIN 02476770 · $0.2042 NRA-Perindopril · DIN 02489023 · $0.2042 PMS-Perindopril · DIN 02470683 · $0.2042 Perindopril Erbumine · DIN 02479885 · $0.2042 Perindopril Erbumine · DIN 02481642 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: resolved shortage (ended 2025-09-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527219
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Perindopril Erbumine · DIN 02482932 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Perindopril Erbumine · DIN 02482932 Manufacturer: Mantra Pharma Inc.; listing date 2021-09-30 Health Canada: Marketed since 2019-07-23 · brand M-PERINDOPRIL ERBUMINE · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Perindopril Erbumine: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97333 · Verify on the e-Formulary ↗ (DIN 02482932)

Source record
DIN 02482932: M-Perindopril Erbumine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id MAT Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2042; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482932 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97333
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Apo-Perindopril · DIN 02289288 · $0.2042 Auro-Perindopril · DIN 02459825 · $0.2042 Coversyl · DIN 02123282 · $0.2042 Jamp Perindopril Erbumine · DIN 02527219 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 Mar-Perindopril · DIN 02474832 · $0.2042 Mint-Perindopril · DIN 02476770 · $0.2042 NRA-Perindopril · DIN 02489023 · $0.2042 PMS-Perindopril · DIN 02470683 · $0.2042 Perindopril Erbumine · DIN 02479885 · $0.2042 Perindopril Erbumine · DIN 02481642 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: resolved shortage (ended 2020-12-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482932
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Perindopril · DIN 02474832 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Perindopril · DIN 02474832 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-06-28 Health Canada: Marketed since 2019-04-11 · brand MAR-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Perindopril: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96502 · Verify on the e-Formulary ↗ (DIN 02474832)

Source record
DIN 02474832: Mar-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id MAR Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2042; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474832 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96502
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Apo-Perindopril · DIN 02289288 · $0.2042 Auro-Perindopril · DIN 02459825 · $0.2042 Coversyl · DIN 02123282 · $0.2042 Jamp Perindopril Erbumine · DIN 02527219 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 M-Perindopril Erbumine · DIN 02482932 · $0.2042 Mint-Perindopril · DIN 02476770 · $0.2042 NRA-Perindopril · DIN 02489023 · $0.2042 PMS-Perindopril · DIN 02470683 · $0.2042 Perindopril Erbumine · DIN 02479885 · $0.2042 Perindopril Erbumine · DIN 02481642 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474832
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Perindopril · DIN 02476770 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Perindopril · DIN 02476770 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2019-04-30 Health Canada: Marketed since 2019-01-23 · brand MINT-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Perindopril: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96761 · Verify on the e-Formulary ↗ (DIN 02476770)

Source record
DIN 02476770: Mint-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id MIN Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2042; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02476770 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96761
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Apo-Perindopril · DIN 02289288 · $0.2042 Auro-Perindopril · DIN 02459825 · $0.2042 Coversyl · DIN 02123282 · $0.2042 Jamp Perindopril Erbumine · DIN 02527219 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 M-Perindopril Erbumine · DIN 02482932 · $0.2042 Mar-Perindopril · DIN 02474832 · $0.2042 NRA-Perindopril · DIN 02489023 · $0.2042 PMS-Perindopril · DIN 02470683 · $0.2042 Perindopril Erbumine · DIN 02479885 · $0.2042 Perindopril Erbumine · DIN 02481642 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02476770
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Perindopril · DIN 02489023 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Perindopril · DIN 02489023 Manufacturer: Nora Pharma; listing date 2020-07-31 Health Canada: Marketed since 2019-10-24 · brand NRA-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Perindopril: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97908 · Verify on the e-Formulary ↗ (DIN 02489023)

Source record
DIN 02489023: NRA-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id NRA Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2042; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489023 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97908
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Apo-Perindopril · DIN 02289288 · $0.2042 Auro-Perindopril · DIN 02459825 · $0.2042 Coversyl · DIN 02123282 · $0.2042 Jamp Perindopril Erbumine · DIN 02527219 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 M-Perindopril Erbumine · DIN 02482932 · $0.2042 Mar-Perindopril · DIN 02474832 · $0.2042 Mint-Perindopril · DIN 02476770 · $0.2042 PMS-Perindopril · DIN 02470683 · $0.2042 Perindopril Erbumine · DIN 02479885 · $0.2042 Perindopril Erbumine · DIN 02481642 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489023
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Perindopril · DIN 02470683 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Perindopril · DIN 02470683 Manufacturer: Pharmascience Inc.; listing date 2018-04-30 Health Canada: Marketed since 2018-03-07 · brand PMS-PERINDOPRIL · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Perindopril: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95969 · Verify on the e-Formulary ↗ (DIN 02470683)

Source record
DIN 02470683: PMS-Perindopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id PMS Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2042; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02470683 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95969
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Apo-Perindopril · DIN 02289288 · $0.2042 Auro-Perindopril · DIN 02459825 · $0.2042 Coversyl · DIN 02123282 · $0.2042 Jamp Perindopril Erbumine · DIN 02527219 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 M-Perindopril Erbumine · DIN 02482932 · $0.2042 Mar-Perindopril · DIN 02474832 · $0.2042 Mint-Perindopril · DIN 02476770 · $0.2042 NRA-Perindopril · DIN 02489023 · $0.2042 Perindopril Erbumine · DIN 02479885 · $0.2042 Perindopril Erbumine · DIN 02481642 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: resolved shortage (ended 2018-11-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02470683
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Perindopril Erbumine · DIN 02479885 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Perindopril Erbumine · DIN 02479885 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-07-31 Health Canada: Marketed since 2019-02-13 · brand PERINDOPRIL ERBUMINE · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Perindopril Erbumine: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97045 · Verify on the e-Formulary ↗ (DIN 02479885)

Source record
DIN 02479885: Perindopril Erbumine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id SIV Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2042; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479885 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97045
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Apo-Perindopril · DIN 02289288 · $0.2042 Auro-Perindopril · DIN 02459825 · $0.2042 Coversyl · DIN 02123282 · $0.2042 Jamp Perindopril Erbumine · DIN 02527219 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 M-Perindopril Erbumine · DIN 02482932 · $0.2042 Mar-Perindopril · DIN 02474832 · $0.2042 Mint-Perindopril · DIN 02476770 · $0.2042 NRA-Perindopril · DIN 02489023 · $0.2042 PMS-Perindopril · DIN 02470683 · $0.2042 Perindopril Erbumine · DIN 02481642 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479885
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Perindopril Erbumine · DIN 02481642 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Perindopril Erbumine · DIN 02481642 Manufacturer: Sanis Health Inc.; listing date 2020-07-31 Health Canada: Marketed since 2022-08-04 · brand PERINDOPRIL ERBUMINE · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Perindopril Erbumine: Formulary list price $0.2042/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2042 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97210 · Verify on the e-Formulary ↗ (DIN 02481642)

Source record
DIN 02481642: Perindopril Erbumine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800209; group id 343; item number 0779; lccId None; manufacturer id SAI Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2042; ministry $0.2042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481642 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97210
Interchangeable products
AG-Perindopril · DIN 02481685 · $0.2042 Apo-Perindopril · DIN 02289288 · $0.2042 Auro-Perindopril · DIN 02459825 · $0.2042 Coversyl · DIN 02123282 · $0.2042 Jamp Perindopril Erbumine · DIN 02527219 · $0.2042 Jamp-Perindopril · DIN 02477017 · $0.2042 M-Perindopril Erbumine · DIN 02482932 · $0.2042 Mar-Perindopril · DIN 02474832 · $0.2042 Mint-Perindopril · DIN 02476770 · $0.2042 NRA-Perindopril · DIN 02489023 · $0.2042 PMS-Perindopril · DIN 02470683 · $0.2042 Perindopril Erbumine · DIN 02479885 · $0.2042 Sandoz Perindopril Erbumine · DIN 02470233 · $0.2042 Teva-Perindopril · DIN 02464993 · $0.2042
Shortage status: resolved shortage (ended 2025-02-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481642
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

LISINOPRIL

· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab

QUINAPRIL

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab

RAMIPRIL

· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (5), General benefit (21) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 34 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph and 19 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications COVERSYL® (perindopril erbumine) is indicated for: • Hypertension o The treatment of mild to moderate essential hypertension. It may be used alone or in association with other drugs, particularly thiazide diuretics. o The safety and efficacy of COVERSYL® in renovascular hypertension have not been established and therefore, its use in this condition is not recommended. o The safety and efficacy of concurrent use of COVERSYL® with antihypertensive agents, other than amlodipine and thiazide diuretics, have not been established. • Congestive Heart Failure o The treatment of mild to moderate congestive heart failure, generally as adjunctive therapy to diuretics, and where appropriate a digitalis glycoside. Treatment should be initiated under close medical supervision. The safety and efficacy of COVERSYL® have not been demonstrated for New York Heart Association Category IV patients. • Hypertensive and/or post-MI patients with stable coronary artery disease. o The reduction of cardiovascular risk in patients with hypert… https://pdf.hres.ca/dpd_pm/00085951.PDF PM date: 2026-08-27 Source product: COVERSYL; DIN 02123274; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications COVERSYL® PLUS LD (perindopril erbumine / indapamide) is indicated for the initial treatment of mild to moderate essential hypertension. COVERSYL® PLUS and COVERSYL® PLUS HD (perindopril erbumine / indapamide) are indicated for the treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. COVERSYL® PLUS and COVERSYL® PLUS HD are not indicated for initial therapy. Patients in whom perindopril and indapamide are initiated simultaneously can develop symptomatic hypotension (see 9 Drug Interactions– Drug-Drug Interactions - Concomitant ACE Inhibitor and Diuretic Therapy). Patients should be titrated on the individual drugs. If the fixed combination represents the dosage determined by this titration, the use of COVERSYL® PLUS or COVERSYL® PLUS HD may prove to be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary, it is advisable to use individual drugs (see 4 Dosage and Administration). The safety and efficacy of COVERSYL® PLUS LD / COVERSYL® PLUS / COVERSYL® PLUS HD in renovascular hypertension and in congestive heart failure have not been established and theref… https://pdf.hres.ca/dpd_pm/00085950.PDF PM date: 2026-08-27 Source product: COVERSYL PLUS LD; DIN 02246568; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Perindopril · DIN 02289261 Shortage status: shortage reported ended 2026-06-18 (report last updated 2026-06-18); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02289261

Check this DIN again

Auro-Perindopril · DIN 02459817 Shortage status: active shortage (reported 2026-06-09, estimated to end 2026-09-30, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02459817

Check this DIN again

Apo-Perindopril · DIN 02289288 Shortage status: shortage reported ended 2026-06-18 (report last updated 2026-06-18); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02289288

Check this DIN again

Auro-Perindopril · DIN 02459825 Shortage status: active shortage (reported 2026-06-09, estimated to end 2026-09-30, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02459825

Check this DIN again